Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | GSK3A | P49840 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8099294 | 0.87 | GSK3B (0.44) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL8040592 | 0.85 | KAT2B (0.52) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4669978 | 0.85 | MAPT (0.46) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL27611246 | 0.84 | GSK3B (0.42) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL3603901 | 0.84 | MAPT (0.45) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL15971839 | 0.83 | TXNRD1 (0.45) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL10270164 | 0.83 | PGK1 (0.42) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL15972357 | 0.83 | HRH3 (0.50) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL3612965 | 0.82 | POLB (0.43) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL3612966 | 0.82 | POLB (0.43) | GSK3BGSK3ACDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989382-B2 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| CN-1717391-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2006-01-04 | — | — | CN | disclosed |
| US-20040138273-A1 | Carbocycle based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138273-A1 | Carbocycle based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.